AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 141 min read$ALHC

KAO JOHN E sold $5.9M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $19.86 ($19.81–$20.65, $5.92M total) across 2 trades on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jul 14, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALHC
Neutral
high confidence
Mentioned
$ALHC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CEO through a pre-arranged 10b5-1 plan; absent other news, it typically does not change fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article does not disclose total insider ownership changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or remaining plan schedule.

Relevance 5/10Novelty 3/10Timing: Filed 2026-07-14 after-hours; transaction dated 2026-07-10.

Background

The article is a SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralHigh confidence
Context

CEO John E. Kao sold $5.9M of Alignment Healthcare shares via a 10b5-1 plan, with 298,000 shares sold at $19.81–$20.65.

Expected impact

Likely limited near-term impact; any effect is typically short-lived unless accompanied by other negative disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly marked as pre-arranged 10b5-1, with no accompanying operational, regulatory, or financial guidance changes in the text.

Market effects

Sector

No sector-level read-through is provided; this is company-specific insider selling.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can reflect planned liquidity needs rather than bearish expectations, so the market may ignore it.

Key entities

  • issuer
    Alignment Healthcare, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    John E. Kao

    CEO and reporting person who sold shares via a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$ALHCMed

Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?

Alignment Healthcare (ALHC) reported Q2 EPS of 17 cents, up from 7 cents a year earlier, with revenue rising 31.6% to $1.34B and beating consensus. Membership reached about 294,100. The company raised 2026 guidance to $5.195B-$5.225B revenue and 298,000-301,000 membership, but expects lower Q3 adjusted EBITDA ($20M-$30M) due to added clinical, AI and expansion spending.

finance.yahoo.com6 min
AUG 3
$ALHCMed

Kaplan Fox Reminds Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors of an Investigation Into Potential Securities Law Violations

Kaplan Fox said a former Alignment Healthcare executive filed a whistleblower complaint alleging accounting irregularities that allegedly inflated reported and projected results, including Adjusted EBITDA, and misclassified operating expenses as capital expenditures. After the July 8, 2026 report, ALHC shares fell $4.02, or 16.7%, to close at $20.03, according to the article.

theglobeandmail.com3 min
JUL 31
$ALHCMed

Alignment Healthcare (ALHC) Stock Trades Down, Here Is Why

Alignment Healthcare (ALHC) shares fell 14.8% after the company said it will reinvest profits, lowering expected second-half 2026 earnings. On its Q2 2026 call, management raised full-year revenue guidance but expects only about 30% of adjusted EBITDA in the second half, versus 40% a year earlier, due to investment timing.

financialcontent.com3 min
JUL 31
$ALHCHighAI 9/10

Alignment Healthcare (ALHC) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - John E. Kao Chief Financial Officer - James Head TAKEAWAYS Health Plan Membership -- 294,000 members, representing 31% growth year over year. Total Revenue -- $1.3 billion, an increase of 32% year over year driven by membership growth. Adjusted MBR -- 86.3%, an improvement of 40 basis points year over year and the lowest since the company went public.

fool.com6 min
JUL 31
$ALHCHighAI 9/10

Alignment Misses Q2 EPS Estimates

Stock falls 12% in after-hours trading Shares in Alignment Healthcare fell 12% in after-hours trading after reporting second quarter results. Orange-based Alignment, a Medicare Advantage provider for seniors, reported earnings per share (EPS) of 17 cents, missing the 20-cent consensus estimate, according to the TheFly.com. The company’s third-quarter revenue outlook of $1.3 billion to $1.32 billion also came in at the low end of Wall Street estimates.

ocbj.com2 min
JUL 30
$ALHCMedAI 8/10

Alignment Healthcare (NASDAQ:ALHC) Beats Q2 CY2026 Sales Expectations But Stock Drops

Health insurance company Alignment Healthcare (NASDAQ: ALHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.6% year on year to $1.34 billion. The company expects next quarter’s revenue to be around $1.31 billion, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 29.8% above analysts’ consensus estimates. Is now the time to buy Alignment Healthcare? Find out by accessing our full research report, it’s free.

financialcontent.com4 min